Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Andre Biuckians

Vascular Surgery Bel Air, MD Medical Doctor

NPI 1184719304 CMS profile 99406

520 Upper Chesapeake Dr, Suite 306, Bel Air, MD 21014

Open in the dashboard

General payments

$24,276

143 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Andre Biuckians of Bel Air, MD is reported in the CMS Open Payments database as having received $24,276 across 143 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,934 25
2024 General $4,824 25
2023 General $9,979 40
2022 General $3,476 12
2021 General $492 12
2020 General $1,330 19
2019 General $242 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Andre Biuckians
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Andre Biuckians were reported at $3,934. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Andre Biuckians Vascular Surgery median Middle half National median
2019 $242 $796 $226–$2,363 $163
2020 $1,330 $348 $118–$1,110 $114
2021 $492 $471 $158–$1,421 $132
2022 $3,476 $725 $222–$2,183 $149
2023 $9,979 $836 $257–$2,440 $160
2024 $4,824 $909 $252–$2,619 $164
2025 $3,934 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Philips Electronics North America Corporation $15,403 25 payments
  2. AngioDynamics, Inc. $3,688 16 payments
  3. Endologix, Inc. $1,105 9 payments
  4. Medtronic, Inc. $928 23 payments
  5. Silk Road Medical, Inc. $468 9 payments
  6. Nevro Corp. $413 4 payments
  7. W. L. Gore & Associates, Inc. $367 3 payments
  8. Boston Scientific Corporation $363 12 payments
  9. Bard Peripheral Vascular, Inc. $362 8 payments
  10. Inari Medical, Inc. $198 2 payments
  11. Other $981 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $13,290 5 payments
  2. Food and Beverage $6,315 123 payments
  3. Travel and Lodging $3,696 14 payments
  4. Honoraria $975 1 payment
Products named General payments · program years 2019–2025
  1. (9520) IGT Devices Undivided $10,358 7 payments
  2. (9520) IGT Devices Und $3,146 2 payments
  3. ANGIOVAC $1,781 2 payments
  4. ALPHAVAC $1,282 2 payments
  5. ENDOCROSS Device $1,105 9 payments
  6. Torus Stent Graft System $1,105 9 payments
  7. IGT D Peripheral $975 1 payment
  8. Abre $603 12 payments
  9. AURYON LASER SYSTEM 100-120 VAC $583 11 payments
  10. ENROUTE Transcarotid Stent $416 8 payments
  11. Other $5,284 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

183

Median for Vascular Surgery: 122

Drug cost

$71,574

Median for Vascular Surgery: $14,135

Branded share of claims

81.4%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 33 $40,237
Eliquis Apixaban Brand 26 $30,034
Clopidogrel Clopidogrel Bisulfate Brand 90 $903
Cilostazol Generic 12 $289
Oxycodone Hcl Generic 22 $110

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 125 billing codes

Paid by Medicare

$690,149

Medicare's payments for the services billed

Medicare patients

1,316

Average age 76

Services billed

2,936

729 women, 587 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 50%
Diabetes 44%
Chronic kidney disease 37%
Heart failure 28%
Atrial fibrillation 28%
Depression 26%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

143 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record